Prescribing Zaleplon (Sonata)

Why Zaleplon Exists

Zaleplon is the shortest-acting hypnotic on the market. Its half-life is roughly 1 hour, shorter than zolpidem (~2.5 h) and dramatically shorter than eszopiclone (5-7 h). That single pharmacokinetic fact defines everything useful and everything limited about the drug.

It buys you a pill that puts someone to sleep quickly and is all but gone within 2 hours, leaving little to no next-morning residue. It costs you a drug that does nothing for sleep-maintenance insomnia. It cannot keep anyone asleep through the night, and it is not FDA-approved to try. Zaleplon is a one-trick agent, and the trick is getting to sleep fast without a hangover.

That makes it useful in two specific situations, both of which turn on its rapid clearance:

1. Sleep-onset insomnia in a patient who has to be sharp early the next morning: the shift worker, the truck driver, the surgeon, the pilot, anyone for whom even a whiff of morning grogginess is unacceptable.
2. Middle-of-the-night awakening, the patient who wakes at 2 or 3 a.m. and can take a dose then, provided there are still at least ~4 hours of intended sleep left before they need to function. That use is off-label: zaleplon's own labeling asks for a full night of sleep remaining.

Keep the whole thing in proportion, though. Across the class, the objective benefit of Z-drugs is modest: pooled FDA-registration data show they get people to sleep about 22 minutes faster than placebo on polysomnography, and only ~7 minutes faster by patients' own report, with no proven improvement in sleep quality or long-term health outcomes. Zaleplon's advantage over its cousins is not that it works better; it is that it works briefly. Prescribe it for the niche, not as a general-purpose sleeping pill, and after behavioral measures have been tried.

Part 1: Indications

FDA-approved use

• Short-term treatment of insomnia characterized by difficulty with sleep onset.

That is the entire label. Note what is absent: no sleep-maintenance indication, because the half-life is too short to hold the second half of the night.

Where it fits

• Sleep-onset insomnia with a hard morning deadline. The defining use case. When residual sedation is a safety issue (operating machinery, driving early, being on call), zaleplon's ~1-hour half-life is what you are paying for.
• Middle-of-the-night dosing. Because it clears so fast, zaleplon can be taken after a nocturnal awakening as long as the patient can still devote roughly 4 hours to sleep afterward. The label is stricter, asking for a full night of sleep remaining (7 to 8 hours), so this is off-label use resting on the one-hour half-life. Sublingual zolpidem is the hypnotic actually labeled for a middle-of-the-night awakening, and its own floor is 4 hours of bedtime remaining.
• PRN / intermittent use. Zaleplon lends itself to as-needed dosing on the nights a patient anticipates trouble, rather than nightly standing use.

Who it is not for

• Sleep-maintenance insomnia (frequent awakenings, early-morning awakening). Wrong drug: it will be gone by 1 a.m. Reach for eszopiclone, low-dose doxepin, or an orexin antagonist instead.
• Patients where behavioral treatment hasn't been tried. CBT-I and sleep hygiene are first-line for chronic insomnia and produce more durable results than any pill. Zaleplon is a late-line, short-term add-on.
• Anyone with a history of a complex sleep behavior on a Z-drug (see Safety): that is an absolute contraindication.

Part 2: How to Start and Dose

Formulations

Immediate-release oral capsules, 5 mg and 10 mg. Generic and inexpensive. There is no extended-release version: an ER zaleplon would defeat the drug's only reason to exist.

Dose

Start at the dose that fits the patient rather than reflexively climbing. For frail, elderly, or hepatically impaired patients, 5 mg is the right starting and often maintenance dose. Efficacy flattens out with dose; the risk of adverse behaviors does not. Higher doses are a leading risk factor for complex sleep behaviors, so there is rarely a good reason to push to 20 mg.

Timing: where zaleplon is different

• Take it in bed, right before intended sleep, not "an hour before, while finishing chores." The onset is rapid and the amnestic window opens fast.
• Middle-of-the-night dosing is off-label. The labeled instruction is a full night of sleep remaining, 7 to 8 hours. If you use zaleplon this way, hold to at least ~4 hours before the patient must be up and functional. Below that margin, next-morning impairment becomes a real risk despite the short half-life.
• Do not eat within 30 minutes of the dose. Food, especially a fatty meal, delays zaleplon's onset by roughly 2 hours (more than zolpidem's ~1-hour food delay). That delayed, prolonged absorption wastes the fast-onset advantage, and it is itself a risk factor for complex sleep behaviors and morning carryover. Counsel patients explicitly: pill on an empty-ish stomach, then straight to bed.

Duration of therapy

Intended as short-term treatment. Reassess after a couple of weeks. If insomnia is chronic, the long-term answer is CBT-I and treating any underlying depression, anxiety, or apnea, not indefinite hypnotic use.

Dose Adjustments, Special Populations, and the Boxed Warning

• Maximum: 20 mg (10 mg is enough for most). Schedule IV.
• Boxed warning (complex sleep behaviors): sleep-walking/driving/eating with amnesia can occur. Zaleplon is contraindicated after any prior episode; stop if one occurs.
• Interactions: metabolized mainly by aldehyde oxidase (not CYP), so few CYP interactions. But cimetidine inhibits aldehyde oxidase and roughly doubles levels (use 5 mg); rifampin (inducer) lowers levels.
• Hepatic impairment: 5 mg in mild-to-moderate; avoid in severe. Renal: no adjustment for mild-to-moderate.
• Geriatric / low body weight: 5 mg. Pregnancy: use only if clearly needed.
• Stopping: short-term use; the ultra-short half-life means little rebound, but taper after regular use.

Part 3: Side Effects and How to Manage Them

Because zaleplon clears so fast, its dose-limiting problems are the behavioral and amnestic ones that happen during the drug's brief window, not next-day sedation.

Next-day impairment: minimal, but not zero

Zaleplon's residual next-morning sedation and cognitive/psychomotor impairment are lower than any other Z-drug's, because of the 1-hour half-life; when taken with a normal night's sleep ahead, most patients wake clear. That is its main advantage. Two caveats: impairment can still appear if the drug is taken too late (insufficient hours before rising) or at the 20 mg dose. Standard hypnotic advice still applies: no driving until the patient knows how they respond.

Complex sleep behaviors (parasomnias): the serious one

Sleepwalking, sleep-driving, sleep-eating, sleep-cooking, making calls or sending texts and emails, even sexual activity, all performed in an amnestic state the patient does not recall. This is a class effect of Z-drugs. FDA calls the episodes rare, and made them the basis of a boxed warning in 2019 because some of them have caused serious injury and death (see Part 4).

Risk factors to actively minimize:

• Higher doses: keep to 5-10 mg.
• Concurrent CNS depressants / other GABA-A agonists: alcohol, benzodiazepines, barbiturates (see Interactions).
• Food before dosing: the delayed/prolonged absorption raises risk.
• Not going straight to bed after the dose.

Management is not subtle: per FDA, any complex sleep behavior, however trivial it seems ("I just microwaved popcorn at 2 a.m."), means the drug is discontinued and not restarted. The rationale is that a mild episode carries the same mechanism as a catastrophic one; the next episode could be sleep-driving into traffic. Do not dose-reduce and continue. Stop it, and switch to a non-GABAergic agent if a hypnotic is still needed.

Anterograde amnesia

Z-drugs impair memory formation for events occurring after the dose. Usually this is harmless (the patient is asleep) but it is the substrate for the parasomnias above, and it produces one more quirk: patients may forget how poorly they actually slept, which inflates their subjective sense of benefit beyond what objective data support. Minimize by dosing immediately before sleep and avoiding co-ingested alcohol or sedatives.

Common nuisance effects

Generally mild and often dose-related: headache, dizziness, drowsiness, and occasionally lightheadedness or a "spacey" feeling. Manage with dose reduction (10 mg to 5 mg) and reassurance that they are typically transient.

Part 4: Overdose and Safety

Boxed warning: complex sleep behaviors

In 2019 the FDA elevated the complex-sleep-behavior warning to boxed-warning status for zaleplon, zolpidem, and eszopiclone, and added a contraindication in anyone who has ever experienced such a behavior on a Z-drug. The agency's 26-year adverse-event review found 66 cases of serious injury or death (46 serious injuries, 20 deaths): falls, burns, near-drownings, hypothermia/cold-exposure with limb loss, carbon-monoxide poisoning, motor-vehicle crashes. The practical rule bears repeating: one episode of any severity means permanent discontinuation.

Overdose in isolation

Taken alone, Z-drug overdose is generally less dangerous than benzodiazepine or barbiturate overdose: the main features are exaggerated pharmacology (sedation, ataxia, confusion) with relatively little respiratory depression in a healthy adult. There is no zaleplon-specific antidote; care is supportive. Flumazenil can reverse the GABA-A effect but is used cautiously and rarely, given seizure risk in mixed ingestions and dependent patients.

The danger: combinations

Serious respiratory depression and death occur when Z-drugs are combined with alcohol, benzodiazepines, opioids, or other CNS depressants. The fatal overdoses come from those combinations. Screen for these, and for the fact that many patients don't consider a nightly glass of wine or a "borrowed" alprazolam relevant to mention.

Other safety notes

• Sleep apnea / respiratory disease: hypnotics blunt respiratory drive, use caution or avoid; screen for undiagnosed apnea (snoring, witnessed pauses, daytime somnolence) before treating "insomnia."
• Falls, especially in the elderly: the short half-life helps, but a middle-of-the-night dose plus a trip to the bathroom is a fall setup.
• Abuse potential: zaleplon is a Schedule IV controlled substance. Misuse is less common than with benzodiazepines but far from absent: in pooled US survey data, 9.2% of people who used a Z-drug reported misusing it, against 17.7% of people who used a benzodiazepine. Avoid in patients with sedative or alcohol use disorders.

Part 5: Drug Interactions

Pharmacokinetics: zaleplon is relatively clean

Unlike zolpidem and eszopiclone (both heavily CYP3A4-dependent), zaleplon is not significantly metabolized through the CYP450 system (it is primarily metabolized by aldehyde oxidase). The practical consequence is that zaleplon is less prone to pharmacokinetic drug interactions than its Z-drug cousins. Patients on the parade of CYP3A4 inhibitors that force dose reductions of zolpidem/eszopiclone (azole antifungals, macrolides such as erythromycin and clarithromycin, certain antiretrovirals, nefazodone, verapamil, grapefruit juice) generally do not require the same juggling with zaleplon.

• One caveat: cimetidine inhibits both aldehyde oxidase (zaleplon's primary route) and CYP3A4 (the secondary one), so it raises zaleplon levels; start at 5 mg in patients taking it.
• Strong enzyme inducers (rifampin, carbamazepine, phenytoin, phenobarbital) can substantially lower zaleplon levels and blunt efficacy.

The pharmacodynamic interactions that matter more

For zaleplon the dangerous interactions are additive CNS/GABA-A effects, not metabolism:

• Avoid: alcohol, benzodiazepines, barbiturates. Additive sedation and respiratory depression, and markedly increased complex-sleep-behavior risk.
• Opioids: combined respiratory depression (FDA warning); use extreme caution.
• Herbal GABA-A agonists: valerian, kava, skullcap; patients rarely disclose these unless asked.
• Valproate: has GABA-A activity; use caution in combination.
• Gabapentin: does not share the GABA-A pharmacodynamic interaction and is acceptable to combine.

Food

Not a drug, but functionally the most important interaction: food delays onset ~2 hours. No dose within 30 minutes of eating (see Dosing).

Part 6: Special Populations

Elderly

• Start at 5 mg; do not exceed 10 mg. Reduced clearance, polypharmacy, and fall risk all argue for the low dose.
• On the plus side, the short half-life makes zaleplon one of the more tolerable Z-drugs in older patients for next-day cognition, but Z-drugs as a class remain flagged by the Beers Criteria as potentially inappropriate in the elderly, so use short-term and prefer non-GABAergic agents (ramelteon, low-dose doxepin, an orexin antagonist, melatonin) when a longer-term hypnotic is needed.

Hepatic impairment

• Zaleplon undergoes significant hepatic metabolism, so impaired clearance raises levels.
• Mild-to-moderate hepatic impairment: 5 mg.
• Severe hepatic impairment: avoid (not adequately studied; accumulation risk).

Renal impairment

• Mild-to-moderate: no dose adjustment generally needed (hepatic clearance dominates).
• Severe / end-stage: limited data, use cautiously; heightened CNS sensitivity is possible.

Pregnancy

• Data are limited. As with hypnotics generally, non-pharmacologic treatment (CBT-I, sleep hygiene) is first-line in pregnancy, and the decision to use any hypnotic weighs medication exposure against the real harms of untreated severe insomnia. Use only if clearly needed, at the lowest dose, and in coordination with obstetrics. Benzodiazepines carry clearer first-trimester teratogenic concern; zaleplon's fetal safety is simply not well characterized, which is a reason for caution, not false reassurance.

Lactation

• Zaleplon is excreted into breast milk in small amounts. Data are sparse. If used, favor the lowest effective dose; the short half-life is theoretically favorable (timing a dose after the last evening feed limits infant exposure), but monitor a nursing infant for sedation and poor feeding, and coordinate with pediatrics.

Children and adolescents

• Not established / not recommended. Safety and efficacy in pediatrics are not established; behavioral measures and (off-label) melatonin are the usual routes when something is needed.

Part 7: Discontinuation

Zaleplon is easier to stop than a benzodiazepine, but two phenomena deserve respect.

• Rebound insomnia: a night or two of insomnia that can transiently feel worse than baseline after stopping, particularly after regular nightly use at higher doses. It is usually brief and self-limited. Warn patients so they don't interpret it as proof they "need" the drug forever.
• Dependence / withdrawal: the risk with Z-drugs is real but substantially lower than with benzodiazepines, and lower still with intermittent PRN use. Physiologic withdrawal (anxiety, tremor, rarely seizures) is largely confined to heavy, prolonged, supratherapeutic use.

How to stop:

• After brief or intermittent use, zaleplon can generally be stopped without a formal taper.
• After sustained nightly use, taper gradually (e.g., step the dose down, or shift to every-other-night, over 1-2 weeks) to blunt rebound insomnia.
• Pair discontinuation with CBT-I / sleep-hygiene reinforcement: treating the underlying insomnia is what prevents the patient from bouncing straight back onto a pill.

Part 8: Zaleplon vs the Alternatives

vs Zolpidem (Ambien). Both are fast-onset Z-drugs for sleep onset. Zaleplon is shorter-acting (t½ ~1 h vs ~2.5 h), so it carries less next-morning impairment and can be dosed later in the night, but zolpidem (as Ambien CR) has a maintenance indication zaleplon lacks. Some clinicians report parasomnias more often with zolpidem, though head-to-head data are thin. Zaleplon also wins on drug interactions (no heavy CYP3A4 dependence).

vs Eszopiclone (Lunesta). Eszopiclone is the long Z-drug (t½ 5-7 h), good for sleep maintenance, but with more next-day carryover and a notorious metallic taste (20-40%). Eszopiclone is CYP3A4-metabolized; zaleplon is not. Choose by the problem: onset-only means zaleplon, staying-asleep means eszopiclone.

vs Benzodiazepines. Zaleplon offers faster onset and less next-day hangover, and misuse is somewhat less common among Z-drug users than among benzodiazepine users. Both classes are GABA-A agonists and share parasomnia, respiratory depression, apnea-worsening, and fall risks, so the old framing of Z-drugs as the categorically safer hypnotic does not hold. For pure sleep-onset trouble in someone who must be sharp early, zaleplon beats a benzodiazepine handily.

vs the non-GABAergic hypnotics (ramelteon, low-dose doxepin, orexin antagonists, melatonin). These are the agents that come closest to avoiding complex sleep behaviors and abuse potential, and are the safer long-term and elderly choices. None of them carries the Z-drug boxed warning, though orexin antagonist and ramelteon labeling warns about complex sleep behaviors too. What zaleplon offers that they don't is a rapid, reliable "get-to-sleep-now" effect, including rescue dosing in the middle of the night. Trade-off: zaleplon's potency and speed vs their safety and durability.

Mechanism

Zaleplon is a non-benzodiazepine ("Z-drug") positive allosteric modulator of the GABA-A receptor. Like the benzodiazepines it potentiates GABA, the brain's principal inhibitory neurotransmitter, but it binds with relative selectivity for GABA-A receptors containing the α1 subunit, the subtype most tied to sedation. That comparative selectivity is the textbook explanation for why Z-drugs deliver hypnotic effect with less of the anxiolytic, myorelaxant, and (somewhat) anterograde-amnestic and dependence baggage of non-selective benzodiazepines.

The clinically decisive feature, though, is pharmacokinetic, not receptor pharmacology: rapid absorption leads to fast onset, and a ~1-hour elimination half-life with metabolism largely by aldehyde oxidase (with some CYP3A4), not the CYP450 pathways that dominate zolpidem and eszopiclone. Fast in, fast out, few interactions.

The Bedside Cheat Sheet